The Hidden Cost of Prior Authorization Delays in Gastroenterology Practices

A patient with Crohn’s disease needs to start a biologic. Your physician writes the order. Then the case sits not because anyone is slow, but because the prior authorization is stuck in a queue, waiting on documentation the payer hasn’t clearly asked for, or a step-therapy requirement that means trying (and failing) a cheaper drug first before the one your physician actually wants to prescribe.

Everyone in gastroenterology knows this friction exists. What’s less visible is what it’s actually costing the practice not just in delayed care, but in dollars, staffing, empty infusion chairs, and patients who quietly go elsewhere while the paperwork works its way through a payer’s queue.

The scale of the problem is bigger than most practices realize

A national survey of gastroenterology providers on prior authorization burden found that 59.5% of practices had hired staff whose job exists purely to manage prior authorizations a direct payroll cost that didn’t exist a decade ago and rarely gets modeled against the revenue those delayed cases represent. More strikingly, 54.4% of respondents reported that at least one of their patients experienced a serious adverse event hospitalization, disability, or worse directly attributed to a prior-authorization-related care delay. Among respondents who recalled at least one such event, the median number recalled over the preceding 12 months was three.

On the financial side, industry data shows that nearly 15% of claims submitted to private payers are initially denied, and prior-authorization-related issues are a recurring driver of that figure. For Gastroenterology practices specifically, more than half of surveyed providers reported that at least weekly, they prescribe a less-preferred therapy simply because the preferred one carries too much PA burden to be worth the fight a decision driven by administrative friction, not clinical judgment, and one that has its own downstream billing consequences when the substituted therapy doesn’t work as well and the patient needs to be escalated again later.

Where the revenue actually disappears

The financial damage from PA delays in gastroenterology billing doesn’t show up as a single line item it shows up in several places at once, which is exactly why it’s easy to underestimate the total impact until someone adds it all up.

Lost Medical Benefit Revenue:

Biologics and infusions billed under the medical benefit (as opposed to a retail pharmacy benefit) are among the highest-reimbursing services a Gastroenterology practice offers. When a case is delayed long enough that a patient is referred out to a hospital infusion center or a specialty pharmacy instead, that revenue along with the ongoing maintenance-dosing relationship, which can run for years leaves the practice permanently, not just for one visit. A single lost biologic patient can represent tens of thousands of dollars in annual infusion revenue that never returns.

Underused Infusion Capacity:

Many Gastroenterology practices have invested in in-office infusion suites specifically because biologic-treated IBD is now standard of care for a growing share of patients. When PA delays create bottlenecks upstream of that capacity, chairs sit empty while nursing and administrative staff are still on the clock a fixed cost that doesn’t shrink just because the pipeline of authorized patients has dried up for the week.

Direct Staffing Cost:

Dedicated PA staff the 59.5% figure above are a real, recurring payroll expense that most practices never model against the revenue those cases would generate if they moved faster. A practice that has quietly built a two- or three-person PA team over the years is carrying a cost center that, done well, should be a revenue enabler instead.

Rework From Incomplete Submissions:

Missing clinical notes, unclear diagnosis coding, or absent step-therapy documentation are the most common reasons a PA request bounces back for more information. Every bounce restarts the clock and adds another round of staff time to a case that hasn’t generated a dollar of revenue yet and each round of back-and-forth increases the odds the patient gets frustrated and seeks care elsewhere before the authorization ever clears.

Peer-to-Peer Review Time:

When a PA is denied outright, the path to overturning it often runs through a peer-to-peer review a phone call between your physician and a payer’s medical reviewer. That’s physician time, arguably the most expensive resource in the practice, spent re-litigating a clinical decision that should have been approved on the documentation already submitted.

Why this is worse for Gastroenterology specifically than for many other specialties

Biologics used to treat inflammatory bowel disease infliximab, adalimumab, vedolizumab, ustekinumab, and others sit at the intersection of high cost, strict step-therapy requirements, and payer scrutiny that’s grown alongside their use over the past several years. Unlike a single-dose procedure, these are ongoing therapy relationships: a delay at initiation doesn’t just push back one appointment, it can disrupt an entire maintenance dosing schedule, each cycle of which may need its own authorization checkpoint depending on the payer and the plan year.

That repeat exposure is why Gastroenterology practices feel PA burden more acutely than specialties where authorization is a one-time hurdle rather than a recurring one. A rheumatology practice or an oncology practice faces some of the same dynamics, but few specialties combine GI’s volume of biologic starts with the sheer diversity of payer-specific step-therapy ladders across the IBD drug class.

What actually reduces the delay and protects the revenue

The practices that handle this well share a few specific habits, not a general commitment to “working harder” on prior auth:

1. Complete documentation on the first submission. The single biggest driver of delay is a PA request that comes back for more information. A submission that includes full clinical notes, diagnosis validation, and documented step-therapy history the first time avoids the resubmission cycle entirely.
2. Standardized, payer-specific workflows. Coverage criteria differ by payer and even by plan within the same payer. Treating every PA request the same way guarantees some of them will be built wrong from the start, and built-wrong requests are the ones that end up in a peer-to-peer queue.
3. Centralized, specialized staff not rotating coverage. PA work handled by whoever has a free hour tends to get deprioritized behind patient-facing tasks. Centralizing it with staff who do nothing else produces measurably faster turnaround and fewer peer-to-peer escalations.
4. Proactive re-authorization tracking for maintenance dosing, so the second, third, and fourth infusion cycles don’t hit the same wall the first one did. A tracking system that flags an upcoming re-authorization deadline two to three weeks out rather than reacting once a claim denies keeps the infusion schedule intact.
5. Real-time payer policy monitoring. Step-therapy requirements and preferred-drug lists shift, sometimes mid-year. A workflow that catches a policy change before your next submission avoids building a request against outdated criteria.

This is also where the case for a specialized billing partner is strongest: general medical billing operations can submit a prior auth request, but a GI-specific team knows which payers require step-therapy documentation for which biologics, and builds submissions to clear on the first pass rather than the third.

Why AffinityCore is the right partner for Gastroenterology prior authorization

Prior authorization for GI biologics isn’t a generic administrative task it requires knowing, drug by drug and payer by payer, exactly what documentation clears a request on the first submission. AffinityCore‘s gastroenterology billing team specializes in exactly this: payer-specific step-therapy requirements for the full IBD biologic class, proactive re-authorization tracking so maintenance dosing never stalls, and a centralized PA workflow built to avoid the resubmission cycle that costs most practices the most time and money. Where a general billing vendor treats prior auth as one more task in a shared queue, AffinityCore treats it as a dedicated function with its own specialized team because for a GI practice, it effectively is one.

If your practice is also evaluating whether to keep this function in-house or bring in outside support altogether, In-House vs Outsourced GI Billing breaks down the real numbers.

Frequently Asked Questions

How long do prior authorizations for GI biologics typically take?

It varies significantly by payer and by drug, ranging from a few days for a clean, complete submission to several weeks when documentation is incomplete or a peer-to-peer review is required. Practices without a standardized workflow tend to see wider variance and more cases stuck at the high end.

What is step therapy, and why does it matter for Gastroenterology billing?

Step therapy requires a patient to try (and typically fail) a lower-cost medication before a payer will approve a physician’s originally prescribed drug. For GI biologics, this can mean weeks of delay before a patient starts the therapy their physician determined was clinically appropriate from the outset and it generates additional documentation burden for the practice at every step.

Can outsourcing prior authorization actually reduce denials, or just move the work?

When done by a team specialized in GI-specific payer requirements, outsourcing typically reduces denials because submissions are built correctly the first time with the right clinical documentation and step-therapy history attached rather than needing multiple rounds of resubmission.

Does prior authorization burden affect reimbursement rates, or just timing?

Primarily timing and completion rate a denied or abandoned PA means the service never gets billed at all, not just billed late. Delayed authorization can also push a case past a payer’s timely-filing window in rare cases, which converts a timing problem into a permanent revenue loss.

What documentation most commonly gets a GI biologic PA rejected on the first pass?

Missing or vague clinical notes, absent documentation of prior therapies tried and failed (required for step therapy), and diagnosis codes that don’t clearly support medical necessity for the specific drug requested are the most common gaps.